Answers are grounded in this paper and cite their sources.
Clinical review reveals significant efficacy alongside gastrointestinal risks of GLP-1 receptor agonists in obesity, highlighting the need for vigilant monitoring and tailored dosing.
While GLP-1RAs are effective in managing obesity, their use is associated with gastrointestinal side effects and rare but serious adverse events. The findings underscore the importance of individualized dosing and thorough patient assessment. Continuous research and vigilant monitoring are essential to optimize their safe use. Further studies are needed to refine guidelines, particularly regarding new concerns such as delayed gastric emptying and its implications for anesthesia.
No takes yet. Share an insight, caveat, or question.
Ghusn et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: